Acrivon Therapeutics, Inc. (ACRV) stock
ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.15−0.25 (-17.86%)
Close on Nov 20, 2026Market cap $49.28MP/E –Yield –
Acrivon Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Acrivon Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$64.14M. For fiscal 2025 it was -$65.33M. The highest annual figure on record is -$14.22M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$65.33M | – |
| FY2024 | Dec 31, 2024 | -$68.44M | – |
| FY2023 | Dec 31, 2023 | -$43.93M | – |
| FY2022 | Dec 31, 2022 | -$32.28M | – |
| FY2021 | Dec 31, 2021 | -$14.22M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.95M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.55M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.18M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.19M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.52M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.38M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.76M | – |
See a number that looks wrong?